Aurinia Pharmaceuticals Inc. Debt Securities, Available-for-sale, Allowance for Credit Loss
Aurinia Pharmaceuticals Inc. (AUPH) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $443.42 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $443.42M.
- 2026-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $378.95M.
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $397.79M.
- 2025-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $351.75M.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $443.42M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $378.95M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $397.79M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $351.75M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $315.23M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $312.92M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $358.32M 10-K · filed 2026-02-26 |
| 2024-09-30 | $348.33M 10-Q · filed 2024-11-07 |
| 2023-12-31 | $350.42M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |